Laboratorios Salvat, S.a.

Chiesi Farmaceutici S.p.a.

Carolina Salcedo Roca

Juan Lorenzo Catena Ruiz

Carmen Lagunas Arnal

Carles Farrerons Gallemi

Andrés Fernandez Garcia

Ignacio José Miquel Bono

Dolors Balsa Lopez

Anna Fernandez Serrat

José Ignacio Bonilla Navarro

Isabel Masip Masip

José Hidalgo Rodriguez

Carmen Serra Comas

Andrés Fernández García

Dolors Balsa López

Anna Fernández Serrat

Natividad Toledo Mesa

Amadeu Llebaria Soldevila

Diego Haro Bautista

Pedro Marrero Gonzalez

Arnau Cordomi Montoya

Carbamate of general formula (I), wherein R1, R2, and R3 are H, OH, NO, SH, CN, F, Cl, Br, I, COOH, CONH, (C-C)-alkoxycarbonyl, (C-C)-alkylsulfanyl, (C-C)-alkylsulfinyl, (C-C)-alkylsulfonyl, (C-C)-alkoxyl optionally substituted with one or several F, and (C-C)-alkyl optionally substituted with one or several F or OH; R4 is cycloalkyl, phenyl, heteroaryl or a bicyclic ring system; R5 is cycloalkyl, (C-C)-alkyl, a substituted (C-C)-alkyl; and Xis a physiologically acceptable anion. Carbamate (I) is selective Mreceptor antagonists versus Mreceptor and may be used for the treatment of urinary incontinence (particularly, the one caused by overactive bladder), irritable bowel syndrome, and respiratory disorders (particularly, chronic obstructive pulmonary disease, chronic bronchitis, asthma, emphysema, and rhinitis), as well as in ophthalmic interventions. 

1-alkyl-1-azoniabicyclo' 2.2.2 octane carbamate derivatives and their use as muscarinic receptor antagonists

Compounds of general formula I, and the salts and solvates thereof, wherein R1 represents the radical 2-benzoylphenylamino; R2 represents &#x2014;(CH)&#x2014;N(COR)-A-J-T or &#x2014;(CH)&#x2014;N(R)&#x2014;B-J-T; and s. R3, R4, A, B, J and T have the meanings disclosed in the description. These compounds are PPAR&#x3b3; modulators and, therefore, are useful for the treatment or prevention of a condition or a disease mediated by these receptors. 

Tyrosine derivatives as PPAR-&#x3b3;-modulators

The invention relates to carbamates having general structure (I), wherein: R1, R2 and R3 are H, OH, SH, CN, F, Cl, Br, I, (C&#x2013;C)-alkylthio, (C&#x2013;C)-alkoxyl, (C&#x2013;C)-alkoxyl substituted by one or several F radicals, carbamoylamine, (C&#x2013;C)alkyl and (C&#x2013;C)alkyl substituted by one or several F or OH radicals; R4 represents a substituted or non-substituted cycloalkyl or cycloaryl radical (a heteroalkyl radical or not). The amine of the quinuclidine ring can also be forming quaternary ammonium salts or in an oxidized state (N-oxide). Carbamates (I) are antagonists of the Mmuscarinic receptor, and selectively, the Mreceptor. Hence, they can be used in the treatment of urinary incontinence (particularly due to bladder instability), irritable bowel syndrome, diseases of the respiratory tract (particularly chronic obstructive pulmonary disease, chronic bronchitis, asthma, emphysema and rhinitis) and in ophthalmologic operations.

Carbamates derived from arylalkylamines

The invention relates to carbamates having general structure (I), wherein: R1, R2 and R3 are H, OH, SH, CN, F, Cl, Br, I, (C-C)-alkylthio, (C-C)-alkoxyl, (C-C)-alkoxyl substituted by one or several F radicals, carbamoylamine, (C-C)-alkyl and (C-C)-alkyl substituted by one or several F or OH radicals; R4 represents a substituted or non-substituted cycloalkyl or cycloaryl radical (a heteroalkyl radical or not). The amine of the quinuclidine ring can also be forming quatemary ammonium salts or in an oxidized state (N-oxide). Carbamates (I) are antagonists of the Mmuscarinic receptor, and selectively, the Mreceptor. Hence, they can be used in the treatment of urinary incontinence (particularly due to bladder instability), irritable bowel syndrome, diseases of the respiratory tract (particularly chronic obstructive pulmonary disease, chronic bronchitis, asthma, emphysema and rhinitis) and in ophthalmologic operations.

Carbamates derivatived from arylakylamines

Growing community of inventors

Corbera, Spain

Carolina Salcedo Roca